{"id":921603,"date":"2025-12-19T16:45:03","date_gmt":"2025-12-19T21:45:03","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/cbdmd-reports-third-consecutive-year-of-operating-improvement-strengthens-balance-sheet-and-regains-nyse-american-continued-listing-compliance\/"},"modified":"2025-12-19T16:45:03","modified_gmt":"2025-12-19T21:45:03","slug":"cbdmd-reports-third-consecutive-year-of-operating-improvement-strengthens-balance-sheet-and-regains-nyse-american-continued-listing-compliance","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/cbdmd-reports-third-consecutive-year-of-operating-improvement-strengthens-balance-sheet-and-regains-nyse-american-continued-listing-compliance\/","title":{"rendered":"cbdMD Reports Third Consecutive Year of Operating Improvement, Strengthens Balance Sheet, and Regains NYSE American Continued Listing Compliance"},"content":{"rendered":"
\n

PR Newswire<\/p>\n<\/p><\/div>\n

\n

\n CHARLOTTE, N.C.<\/span>, Dec. 19, 2025<\/span> \/PRNewswire\/ — cbdMD, Inc. (NYSE American: YCBD)<\/i>, one of the nation’s leading and most highly trusted and recognized CBD companies, and operator of the leading CBD brands cbdMD and Paw CBD,<\/i> along with hemp derived THC beverage line Herbal Oasis<\/i> today announced our financial results for the full fiscal year ended September 30, 2025.<\/p>\n

\n

\n
\n \"cbdMD
\n <\/a>\n <\/p>\n<\/p><\/div>\n

For fiscal year 2025, cbdMD delivered its third consecutive year of operational and financial improvement, reflecting disciplined cost management, focused execution, and continued investment in quality and science.<\/p>\n

The Company reported a loss from operations of $2.1 million, representing a $1.2 million year-over-year improvement from a $3.3 million operating loss in fiscal 2024. As a result of balance-sheet actions completed during the year, including the conversion of Series A preferred equity, net book value improved from under $2.0 million to approximately $7.2 million at year-end.\u00a0 The Company took further steps this week to strengthen its balance sheet and raised an additional $2.25 million in gross proceeds from the sale of Series C Convertible Preferred Stock.\u00a0 Management believes the current capital structure provides flexibility to support growth initiatives and opportunities ahead in 2026.<\/p>\n

“Fiscal 2025 marked an important inflection point for cbdMD as we delivered our third straight year of operating improvement while completing several foundational balance-sheet and compliance milestones,” said Ronan Kennedy, CEO and CFO of cbdMD. “We believe our performance during the September quarter compared favorably with many of our public peers and reflects the early impact of strategic changes we made to our sales and marketing organization.”<\/p>\n

“Our core cbdMD business continues to gain traction, and our Herbal Oasis team is seeing consistent month-over-month improvement in case sell-through across key markets as distribution expands throughout the Southeast. Importantly, we have paired this commercial momentum with a disciplined approach to capital allocation and balance-sheet management.”<\/p>\n

“As federal policy discussions continue to evolve around cannabinoids and hemp-derived products, cbdMD remains focused on operating at the highest standards of safety, quality, and scientific rigor,” Kennedy continued. “Since our founding, we have invested millions of dollars in GMP manufacturing, product testing, and compliance systems to ensure our products meet or exceed applicable regulatory expectations.”<\/p>\n

\u00a0“We are very encouraged by the White House’s executive order on Thursday.\u00a0 We believe decriminalization will allow significant investment to further prove the benefits of cannabinoids. Since our formation, we have invested millions to ensure we provide safe, effective cannabinoid products that meet high-GMP quality standards. What makes us most excited are the statements around Medicare supporting the reimbursement of full spectrum hemp for seniors.\u00a0 This gives us confidence the regulators will figure out how to rework the language in Novembers’ H.R. 5371 to more palatable language. There are over 60 million seniors on Medicaid who have the potential to become regular consumers to our core market.<\/p>\n

“We believe increasing regulatory clarity will encourage additional research and institutional investment across the category. With our long-standing emphasis on THC-free and broad-spectrum CBD formulations, as well as our experience responsibly operating in hemp-derived THC beverages, cbdMD is well positioned to adapt as regulatory frameworks mature.”<\/p>\n

“With a stronger balance sheet, restored exchange compliance, improving operations, and a disciplined approach to growth, we believe cbdMD enters calendar 2026 in a materially stronger position,” Kennedy concluded. “Our focus remains on executing responsibly, investing in science and quality, and creating long-term value for shareholders.”<\/p>\n

\n
\n Highlights for Fiscal 2025 and Notable Business Updates\u00a0 <\/u>
\n <\/b>\n <\/p>\n